InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Monday, 10/14/2019 7:53:07 PM

Monday, October 14, 2019 7:53:07 PM

Post# of 3833
Interesting report - out of $18 B potential market 62% is for NASH - CX and GALT is only co with P3 ready drug. It is very attractive and overdue to get P3 approved by FDA


https://www.globaldata.com/global-nash-market-set-reach-18-3bn-2026/


“The total size of the non-alcoholic steatohepatitis (NASH) market across the 7MM* is set to grow from $138.4M in 2016 to $18.3bn in 2026 at a compound annual growth rate (CAGR) of 63%, according to GlobalData, a leading data and analytics company.


GlobalData’s report also finds that drugs which are proven to benefit NASH patients with cirrhosis will account for the largest segment of the NASH market. The company expects these drugs to account for 62% of the NASH market in 2026, with total sales of $11.3bn.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News